Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	210 mg Brodalumab
Total, all-cause mortality	140 mg Brodalumab
Total, all-cause mortality	Placebo
Total, all-cause mortality	Ustekinumab
Total, other adverse events	210 mg Brodalumab	353	624
Total, other adverse events	140 mg Brodalumab	329	629
Total, other adverse events	Placebo	152	315
Total, other adverse events	Ustekinumab	168	313
Total, serious adverse events	210 mg Brodalumab	9	624
Total, serious adverse events	140 mg Brodalumab	10	629
Total, serious adverse events	Placebo	3	315
Total, serious adverse events	Ustekinumab	2	313

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01708629/event-totals